Exosome & Amniotic 'Regenerative' Products: The Illegal-Marketing Angle
Acellular Birth-Tissue and Exosome Vials Marketed for Sexual Health, Unapproved and Often Illegally Promoted
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA-approved exosome/amniotic product for ED; FDA has issued public safety warnings
Reference only. Not medical advice.
What can go wrong
Documented and plausible harms: serious infections (the FDA's 2019 alert cited adverse events including infections after unapproved exosome products), immune reactions to allogeneic birth tissue, and the universal harms of paying $1,000s for an unproven, often-acellular product while forgoing effective care. Sterility and content of these vials are frequently unverified. This is the lowest-evidence, highest-misrepresentation tier in the regenerative-ED landscape.
This is something to take to a clinician. The Atlas can tell you what is known about exosome & amniotic 'regenerative' products: the illegal-marketing angle in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Exosomes are extracellular vesicles secreted by cells that carry proteins and RNA; amniotic/umbilical-cord products are processed birth tissues. Clinics market both as 'regenerative' add-ons for ED and sexual health, often bundled with PRP or shockwave. The hard fact: as of the FDA's December 2019 public safety notification, there are NO FDA-approved exosome products for any indication, and the agency warned of serious adverse events (including infections) tied to unapproved exosome products. Amniotic/cord 'stem cell' products marketed this way are typically acellular and regulated as drugs/biologics requiring approval they do not have. Marketing these for ED is generally unapproved and, where disease claims are made, runs into illegal-promotion territory the FDA and FTC police.
There are zero FDA-approved exosome products for any disease, yet they're sold for sexual health.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The theoretical pitch: exosomes deliver growth-factor and microRNA 'signals' that instruct host tissue to regenerate; amniotic/cord tissue supplies a matrix and putative cells. In reality, commercial preparations are non-standardized, their exosome content and bioactivity are unverified, and birth-tissue products are usually processed/frozen to the point of being acellular. There is no controlled human ED evidence. The mechanism is a marketing narrative grafted onto products whose actual contents are frequently uncharacterized.
The catch: it is the contents AND the claims that are the problem
Two distinct issues compound. First, contents: independent testing of commercial amniotic/cord and exosome products repeatedly finds far fewer active components (or viable cells) than implied. Second, regulation: exosomes and acellular birth-tissue products that are more-than-minimally manipulated or used for non-homologous purposes are drugs/biologics requiring FDA approval, which none have for ED. When a clinic claims these treat a disease, that is unapproved-new-drug promotion the FDA can act on, and unsubstantiated efficacy claims draw FTC scrutiny. The 2019 FDA exosome alert explicitly flagged patient harm, not just regulatory technicality.
What people get wrong
Often saidExosomes are an approved regenerative therapy
ActuallyThere are zero FDA-approved exosome products for any disease. Marketing them to treat ED is unapproved.
Often saidAmniotic 'stem cell' shots contain potent live cells
ActuallyMost are acellular by the time of injection; you are paying for a processed-tissue product, not live stem cells.
Often saidIt's natural birth tissue, so it's safe
ActuallyThe FDA has linked unapproved exosome/birth-tissue products to serious infections; safety and sterility are not assured.
Who profits, and who pushes back
U.S. Food and Drug Administration
There are no FDA-approved exosome products; some patients receiving unapproved products have experienced serious adverse events including infections.
Federal Trade Commission
Unsubstantiated disease-treatment claims for regenerative products are deceptive and subject to enforcement.
What we do not know
- Can any standardized, well-characterized exosome product show controlled ED benefit?
- How widespread is acellular/misbranded product in the ED upsell market?
- Will FDA/FTC enforcement keep pace with clinic marketing?
At a glance
- FDA-approved exosome products
- Zero (any indication)
- FDA safety alert
- December 2019 (adverse events, infections)
- Amniotic 'stem cell' content
- Typically acellular when injected
- Typical price
- $1,000-$5,000+ per vial/session
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Exosome & Amniotic 'Regenerative' Products: The Illegal-Marketing Angle. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA Public Safety Notification2019
FDA warned consumers and providers that no exosome products are approved and that unapproved products were linked to serious adverse events including infections
Independent product testing (e.g., Berger et al.)2019
Commercial amniotic/cord 'stem cell' products found to contain few or no viable cells, undermining marketing claims